Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)
Key facts
- Who runs it
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 76 people enrolled
- Started
- 28 Apr 2026
- Ended
- 24 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oral Immunomodulator
- Vaginal Ovule
- Standard Supportive Care
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Female patients aged 18-65 years
- Confirmed persistent high-risk human papillomavirus (HR-HPV) infection
- Histologically confirmed CIN 1 or cytological diagnosis of ASC-US or LSIL
- Eligible for conservative follow-up without immediate excisional treatment
- Ability to provide written informed consent and comply with study procedures
Who cannot take part
- Immunodeficiency or current immunosuppressive therapy
- Previous treatment for cervical dysplasia within the last 6 months
- HSIL, CIN2, CIN3, adenocarcinoma in situ, or invasive cervical cancer
- Known hypersensitivity to any study intervention
- Pregnancy or breastfeeding
- Planned colposcopy, cervical biopsy, or LEEP during the 3-month study period
- Participation in another interventional clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Persistent high-risk human papillomavirus infection is an important precursor of cervical cancer and related cervical lesions. This single-center, randomized, assessor-blinded, parallel-group controlled trial evaluates whether dual-modality immunotherapy consisting of an oral immunomodulator plus a vaginal ovule improves HPV clearance compared with standard supportive care. A total of 76 participants will be randomized in a 1:1 ratio. The primary outcome is HPV clearance confirmed by repeat HPV testing and cervical cytology after the 3-month treatment period. Treatment adherence and adverse events will also be monitored.
The 2 groups in the trial
- Dual-Modality ImmunotherapyTreatment being tested
Participants receive an oral immunomodulator twice daily together with a vaginal ovule administered for 14 consecutive days each month for 3 months.
Treatment: Oral Immunomodulator and Vaginal Ovule
- Standard Supportive CareExisting treatment, for comparison
Participants receive standard supportive care for 3 months according to routine clinical practice.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial to Evaluate the Efficacy of a Dual-Modality Immunotherapy (Oral Immunomodulator and Vaginal Ovule) for Human Papillomavirus (HPV) Clearance
- Record updated
- 29 July 2026